Bristol-Myers profit slightly tops Wall Street view on blood thinner sales
April 25, 2019 at 07:00 AM EDT
U.S drugmaker Bristol-Myers Squibb Co, which is set to buy biotechnology company Celgene Corp for $74 billion, posted slightly better-than-expected first-quarter earnings on Thursday on strong sales of its blockbuster blood thinner Eliquis.
